Multiple Sclerosis Journal

Papers
(The H4-Index of Multiple Sclerosis Journal is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No80
Progression independent of relapse activity in multiple sclerosis: Time to account for cognitive decline77
Time to move past typical syndromes in the diagnosis of multiple sclerosis75
Sars-CoV2 infection in pregnant women with multiple sclerosis69
Reply to letter to the editor: Olfactory threshold as a biomarker of disease activity60
Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient58
All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: Yes53
Therapy challenges for NMOSD in a patient with HIV50
Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis48
Thematic analysis of multiple sclerosis research by enhanced strategic diagram41
The MoXFo initiative – study design: Considerations related to study design and methodology in exercise research for people with multiple sclerosis40
Severe course of tick-borne encephalitis (TBE) in a patient with relapsing multiple sclerosis (MS) treated with ocrelizumab39
Erratum to “Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis” Multiple Sclerosis Journal; 2024: 30(8); 1086–1088. DOI: 10.1177/13524585241260564.37
GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple sclerosis37
An interdisciplinary approach is necessary in the treatment of cognitive decline in MS: No36
Decentralised clinical trials in multiple sclerosis research36
Double-negative neuromyelitis optica spectrum disorder36
Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity35
Productivity loss among people with early multiple sclerosis: A Canadian study33
Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Commentary33
Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years30
Characterizing financial toxicity among people living with neuromyelitis optica spectrum disorder30
Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series29
Cerebrospinal fluid–related tissue damage in multiple sclerosis patients with iron rim lesions29
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO29
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary29
Low-dose rituximab should be used for treating MS in resource-limited settings: Commentary28
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions28
0.46352410316467